Literature DB >> 21974797

Neuroendocrine tumor presenting like lymphoma: a case report.

Riccardo Del Vescovo1, Roberto Luigi Cazzato, Sofia Battisti, Francesco D'Agostino, Bruno Vincenzi, Rosario Francesco Grasso, Bruno Beomonte Zobel.   

Abstract

INTRODUCTION: Neuroendocrine tumors are a rare but diverse group of malignancies that arise in a wide range of organ systems, including the mediastinum. Differential diagnosis includes other masses arising in the middle mediastinum such as lymphoma, pericardial, bronchogenic and enteric cysts, metastatic tumors, xanthogranuloma, systemic granuloma, diaphragmatic hernia, meningocele and paravertebral abscess. CASE
PRESENTATION: We present a case of 42-year-old Caucasian man with a neuroendocrine tumor of the middle-posterior mediastinum and liver metastases, which resembled a lymphoma on magnetic resonance imaging.
CONCLUSION: The differential diagnosis in patients with mediastinal masses and liver lesions should include neuroendocrine tumor.

Entities:  

Year:  2011        PMID: 21974797      PMCID: PMC3195764          DOI: 10.1186/1752-1947-5-506

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  12 in total

Review 1.  Primary hepatic neuroendocrine tumor: an unusual cystic presentation.

Authors:  Prasad K Shetty; Sameer V Baliga; K Balaiah; Prakash S Gnana
Journal:  Indian J Pathol Microbiol       Date:  2010 Oct-Dec       Impact factor: 0.740

Review 2.  Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques.

Authors:  T D Atwell; J W Charboneau; F G Que; J Rubin; B D Lewis; D M Nagorney; M R Callstrom; M A Farrell; H C Pitot; T J Hobday
Journal:  Cardiovasc Intervent Radiol       Date:  2005 Jul-Aug       Impact factor: 2.740

3.  Hodgkin disease: contributions of chest CT in the initial staging evaluation.

Authors:  R A Castellino; N Blank; R T Hoppe; C Cho
Journal:  Radiology       Date:  1986-09       Impact factor: 11.105

4.  Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy.

Authors:  Mary K G McStay; Dave Maudgil; Martin Williams; Jonathan M Tibballs; Anthony F Watkinson; Martyn E Caplin; John R Buscombe
Journal:  Radiology       Date:  2005-09-28       Impact factor: 11.105

Review 5.  Tumors of the mediastinum.

Authors:  Beau V Duwe; Daniel H Sterman; Ali I Musani
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

6.  Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.

Authors:  Clarisse Dromain; Thierry de Baere; Jean Lumbroso; Hubert Caillet; Agnès Laplanche; Valerie Boige; Michel Ducreux; Pierre Duvillard; Dominique Elias; Martin Schlumberger; Robert Sigal; Eric Baudin
Journal:  J Clin Oncol       Date:  2005-01-01       Impact factor: 44.544

Review 7.  Primary mediastinal tumors: part II. Tumors of the middle and posterior mediastinum.

Authors:  D C Strollo; M L Rosado-de-Christenson; J R Jett
Journal:  Chest       Date:  1997-11-05       Impact factor: 9.410

Review 8.  Uncommon primary mediastinal tumours.

Authors:  Paolo Macchiarini; Helmut Ostertag
Journal:  Lancet Oncol       Date:  2004-02       Impact factor: 41.316

Review 9.  Neuroendocrine tumors: role of interventional radiology in therapy.

Authors:  Michael J Steward; Victoria S Warbey; Anmol Malhotra; Martyn E Caplin; John R Buscombe; Dominic Yu
Journal:  Radiographics       Date:  2008 Jul-Aug       Impact factor: 5.333

10.  Non-Hodgkin lymphoma: contribution of chest CT in the initial staging evaluation.

Authors:  R A Castellino; S Hilton; J P O'Brien; C S Portlock
Journal:  Radiology       Date:  1996-04       Impact factor: 11.105

View more
  1 in total

1.  Mediastinal small cell carcinoma with liver and bone marrow metastasis, mimicking lymphoma.

Authors:  Napaporn Nawarawong; Tawatchai Pongpruttipan; Pitulak Aswakul; Varayu Prachayakul
Journal:  World J Clin Cases       Date:  2015-10-16       Impact factor: 1.337

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.